Stocks and Investing
Stocks and Investing
Fri, July 25, 2014
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Thu, July 24, 2014
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Evan Seigerman Maintained (BIIB) at Buy with Increased Target to $425 on, Jul 24th, 2014
Evan Seigerman of Credit Suisse, Maintained "Biogen Inc." (BIIB) at Buy with Increased Target from $400 to $425 on, Jul 24th, 2014.
Evan has made no other calls on BIIB in the last 4 months.
There are 2 other peers that have a rating on BIIB. Out of the 2 peers that are also analyzing BIIB, 0 agree with Evan's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Evan
- Cory Kasimov of "JP Morgan" Upgraded from Hold to Buy and Increased Target to $375 on, Thursday, May 29th, 2014
- Matthew Harrison of "Morgan Stanley" Initiated at Buy and Held Target at $395 on, Thursday, March 27th, 2014
Contributing Sources